WC
SLN

Wexford Capital’s Silence Therapeutics SLN Stock Holding History

Wexford Capital’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,708
Closed -$40K – 516
2025
Q3 		$40K Sell
7,708
-19,441
-72% -$108K 0.01% 329
2025
Q2 		$157K Buy
+27,149
New +$116K 0.04% 189

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Wexford Capital's SLN Position: Q4 2025 in Review

Wexford Capital sold out of Silence Therapeutics (SLN) in Q4 2025, closing a stake of 7,708 shares — an estimated $40K sold.

Wexford Capital first reported a position in SLN in Q2 2025 and held it in 2 quarters. The position peaked at $157K in Q2 2025. 58 funds tracked by Wall St. Rank hold SLN as of Q4 2025.

  • Wexford Capital reported no remaining Silence Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wexford Capital sold 7,708 Silence Therapeutics shares in Q4 2025, an estimated $40K.
  • Wexford Capital first reported a position in Silence Therapeutics in Q2 2025 and held it in 2 quarters.
  • Wexford Capital's Silence Therapeutics position peaked at $157K in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.